The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Speakers' Bureau - Chugai Pharma; Nippon Kayaku; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Nippon Kayaku (Inst); Yakult Honsha (Inst)
 
Speakers' Bureau - Astellas Pharma; AstraZeneca; Chugai Pharma; Novartis
Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy inadvanced nonsquamous non–small cell lung cancer (WJOG 5910L): An open-label, randomized, phase II trial.
 
Masayuki Takeda
No Relationships to Disclose
 
Takashi Seto
Speakers' Bureau - AstraZeneca; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Fuji Pharma; Hisamitsu Pharmaceutical; Kyowa Hakko Kirin; Lilly; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Hidetoshi Hayashi
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly
Speakers' Bureau - AstraZeneca; Lilly; Merck Serono
 
Morihito Okada
No Relationships to Disclose
 
Koichi Azuma
No Relationships to Disclose
 
Shunichi Sugawara
No Relationships to Disclose
 
Haruko Daga
No Relationships to Disclose
 
Tomonori Hirashima
Research Funding - AstraZeneca (Inst); Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Kimio Yonesaka
No Relationships to Disclose
 
Yoshiko Urata
No Relationships to Disclose
 
Haruyasu Murakami
Consulting or Advisory Role - Astellas Pharma; Clovis Oncology
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo; Nippon Boehringer Ingelheim; Nippon Kayaku; Pfizer; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Novartis (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst)
 
Haruhiro Saito
No Relationships to Disclose
 
Akihito Kubo
Honoraria - Chugai Pharma
 
Toshiyuki Sawa
No Relationships to Disclose
 
Eiji Miyahara
No Relationships to Disclose
 
Naoyuki Nogami
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Lilly; Nippon Boehringer Ingelheim; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Takeharu Yamanaka
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; MSD; Taiho Pharmaceutical; Takeda
 
Yoichi Nakanishi
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma (Inst)
 
Kazuhiko Nakagawa
Honoraria - Chugai Pharma
Speakers' Bureau - Chugai Pharma
Research Funding - Chugai Pharma (Inst)
 
Isamu Okamoto
Honoraria - Chugai Pharma